Innoviva (FRA:HVE) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HVE Innoviva Inc FRA:HVE
86 GF Score
Price €18.30
GF Value €21.20
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innoviva Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoviva  (FRA:HVE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Innoviva Cyclically Adjusted PB Ratio Related Terms


Innoviva Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Innoviva's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva Cyclically Adjusted PB Ratio Chart

Innoviva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.71 5.69 6.07 4.44 2.99

Innoviva Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.35 3.62 3.53 3.78 3.47

FRA:HVE vs SLBT, MAZE, NVAX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted PB Ratio falls into.


FRA:HVE
86GF Score
Innoviva Inc FRA:HVE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innoviva Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Innoviva's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Innoviva's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.85/333.9520*333.9520
=14.850

Current CPI (Jun. 2026) = 333.9520.

Innoviva Quarterly Data

Book Value per Share CPI Adj_Book
201609 -2.988 241.428 -4.133
201612 -3.086 241.432 -4.269
201703 -2.861 243.801 -3.919
201706 -2.379 244.955 -3.243
201709 -1.746 246.819 -2.362
201712 -1.984 246.524 -2.688
201803 -1.707 249.554 -2.284
201806 -1.311 251.989 -1.737
201809 -0.923 252.439 -1.221
201812 1.376 251.233 1.829
201903 1.760 254.202 2.312
201906 2.139 256.143 2.789
201909 2.570 256.759 3.343
201912 3.009 256.974 3.910
202003 3.651 258.115 4.724
202006 4.328 257.797 5.607
202009 4.499 260.280 5.772
202012 4.900 260.474 6.282
202103 5.845 264.877 7.369
202106 4.778 271.696 5.873
202109 6.107 274.310 7.435
202112 6.648 278.802 7.963
202203 7.131 287.504 8.283
202206 7.759 296.311 8.745
202209 9.383 296.808 10.557
202212 7.662 296.797 8.621
202303 7.851 301.836 8.686
202306 7.800 305.109 8.537
202309 9.205 307.789 9.987
202312 9.652 306.746 10.508
202403 10.376 312.332 11.094
202406 9.926 314.175 10.551
202409 9.569 315.301 10.135
202412 10.651 315.605 11.270
202503 9.541 319.799 9.963
202506 9.664 322.561 10.005
202509 11.496 324.800 11.820
202512 13.380 324.054 13.789
202603 15.776 330.213 15.955
202606 14.850 333.952 14.850

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Innoviva (FRA:HVE) Overvalued in 2026?

Based on GuruFocus' analysis, Innoviva stock appears to be undervalued. The current stock price of €18.30 is trading 13.7% below its estimated GF Value™ of €21.20. GuruFocus considers Innoviva to be Modestly Undervalued.

Key valuation signals for FRA:HVE:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €21.20 vs. price of €18.30 (13.7% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the FRA:HVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innoviva Business Description

Other Exchanges INVA:USA
Address 1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
86GF Score

Get the complete analysis for FRA:HVE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.30
Price
€21.20
GF Value